New Data, New Perspectives in Ovarian Cancer: Experts Discuss the Current Paradigm and Long-term Benefits of PARP Inhibitor Therapy

Watch this on-demand webcast capturing a live CCO webinar during IGCS 2021 of experts discussing the evolving strategies and expanding role of PARP inhibitors in managing patients with ovarian cancer.

Nicoletta Colombo, MD Philipp Harter, MD, PhD Alexandra Leary, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: October 4, 2021 Expired: No longer available for credit

Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with ovarian cancer.

Nicoletta Colombo, MD Released: September 3, 2021

Download this slideset discussing a clinical case of PARP inhibitors for a patient with ovarian cancer.

Philipp Harter, MD, PhD Released: September 3, 2021

Download this slideset on maintenance strategies for newly diagnosed patients with BRCA1/2-mutated ovarian cancer.

Alexandra Leary, MD, PhD Released: September 3, 2021

Download this short summary slideset of key takeaway points from a live presentation on the global perspectives on the current paradigm and long term benefits of PARPi in the treatment of ovarian cancer. 

Nicoletta Colombo, MD Philipp Harter, MD, PhD Alexandra Leary, MD, PhD Released: September 10, 2021

Listen to Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live CCO webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer.

Nicoletta Colombo, MD Philipp Harter, MD, PhD Alexandra Leary, MD, PhD Released: October 14, 2021

In this downloadable PDF transcript from a CCO podcast, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live CCO webinar focused on best management strategies in ovarian cancer treatment.

Nicoletta Colombo, MD Philipp Harter, MD, PhD Alexandra Leary, MD, PhD Released: October 19, 2021

Read this expert commentary to gain practical clinical insights on the current treatment landscape of PARP inhibitors and the role of biomarkers in ovarian cancer.

Nicoletta Colombo, MD Released: November 2, 2021